These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 33230178)

  • 1. Central nervous system pathology in preclinical MPS IIIB dogs reveals progressive changes in clinically relevant brain regions.
    Egeland MT; Tarczyluk-Wells MM; Asmar MM; Adintori EG; Lawrence R; Snella EM; Jens JK; Crawford BE; Wait JCM; McCullagh E; Pinkstaff J; Cooper JD; Ellinwood NM
    Sci Rep; 2020 Nov; 10(1):20365. PubMed ID: 33230178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A model of mucopolysaccharidosis IIIB (Sanfilippo syndrome type IIIB): N-acetyl-alpha-D-glucosaminidase deficiency in Schipperke dogs.
    Ellinwood NM; Wang P; Skeen T; Sharp NJ; Cesta M; Decker S; Edwards NJ; Bublot I; Thompson JN; Bush W; Hardam E; Haskins ME; Giger U
    J Inherit Metab Dis; 2003; 26(5):489-504. PubMed ID: 14518829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB.
    Wilkinson FL; Holley RJ; Langford-Smith KJ; Badrinath S; Liao A; Langford-Smith A; Cooper JD; Jones SA; Wraith JE; Wynn RF; Merry CL; Bigger BW
    PLoS One; 2012; 7(4):e35787. PubMed ID: 22558223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB.
    Ellinwood NM; Valentine BN; Hess AS; Jens JK; Snella EM; Jamil M; Hostetter SJ; Jeffery ND; Smith JD; Millman ST; Parsons RL; Butt MT; Chandra S; Egeland MT; Assis AB; Nelvagal HR; Cooper JD; Nestrasil I; Mueller BA; Labounek R; Paulson A; Prill H; Liu XY; Zhou H; Lawrence R; Crawford BE; Grover A; Cherala G; Melton AC; Cherukuri A; Vuillemenot BR; Wait JCM; O'Neill CA; Pinkstaff J; Kovalchin J; Zanelli E; McCullagh E
    J Pharmacol Exp Ther; 2022 Sep; 382(3):277-286. PubMed ID: 35717448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of cerebellar pathology in the canine model of mucopolysaccharidosis type IIIA (MPS IIIA).
    Hassiotis S; Jolly RD; Hemsley KM
    Mol Genet Metab; 2014 Dec; 113(4):283-93. PubMed ID: 25453402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporospatial Development of Neuropathologic Findings in a Canine Model of Mucopolysaccharidosis IIIB.
    Harm TA; Hostetter SJ; Nenninger AS; Valentine BN; Ellinwood NM; Smith JD
    Vet Pathol; 2021 Jan; 58(1):205-222. PubMed ID: 33205707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential distribution of heparan sulfate glycoforms and elevated expression of heparan sulfate biosynthetic enzyme genes in the brain of mucopolysaccharidosis IIIB mice.
    McCarty DM; DiRosario J; Gulaid K; Killedar S; Oosterhof A; van Kuppevelt TH; Martin PT; Fu H
    Metab Brain Dis; 2011 Mar; 26(1):9-19. PubMed ID: 21225451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trehalose reduces retinal degeneration, neuroinflammation and storage burden caused by a lysosomal hydrolase deficiency.
    Lotfi P; Tse DY; Di Ronza A; Seymour ML; Martano G; Cooper JD; Pereira FA; Passafaro M; Wu SM; Sardiello M
    Autophagy; 2018; 14(8):1419-1434. PubMed ID: 29916295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B.
    Heldermon CD; Hennig AK; Ohlemiller KK; Ogilvie JM; Herzog ED; Breidenbach A; Vogler C; Wozniak DF; Sands MS
    PLoS One; 2007 Aug; 2(8):e772. PubMed ID: 17712420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical evaluation of intracerebroventricular rhNAGLU-IGF2 enzyme replacement therapy in neonatal mice with Sanfilippo B syndrome.
    Kan SH; Elsharkawi I; Le SQ; Prill H; Mangini L; Cooper JD; Lawrence R; Sands MS; Crawford BE; Dickson PI
    Mol Genet Metab; 2021 Jun; 133(2):185-192. PubMed ID: 33839004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competitive binding of extracellular accumulated heparan sulfate reduces lysosomal storage defects and triggers neuronal differentiation in a model of Mucopolysaccharidosis IIIB.
    De Pasquale V; Scerra G; Scarcella M; D'Agostino M; Pavone LM
    Biochim Biophys Acta Mol Cell Res; 2021 Oct; 1868(11):119113. PubMed ID: 34329663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysosomal storage of heparan sulfate causes mitochondrial defects, altered autophagy, and neuronal death in the mouse model of mucopolysaccharidosis III type C.
    Pshezhetsky AV
    Autophagy; 2016 Jun; 12(6):1059-60. PubMed ID: 25998837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuated plasticity in neurons and astrocytes in the mouse model of Sanfilippo syndrome type B.
    Li HH; Zhao HZ; Neufeld EF; Cai Y; Gómez-Pinilla F
    J Neurosci Res; 2002 Jul; 69(1):30-8. PubMed ID: 12111813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB.
    Kan SH; Aoyagi-Scharber M; Le SQ; Vincelette J; Ohmi K; Bullens S; Wendt DJ; Christianson TM; Tiger PM; Brown JR; Lawrence R; Yip BK; Holtzinger J; Bagri A; Crippen-Harmon D; Vondrak KN; Chen Z; Hague CM; Woloszynek JC; Cheung DS; Webster KA; Adintori EG; Lo MJ; Wong W; Fitzpatrick PA; LeBowitz JH; Crawford BE; Bunting S; Dickson PI; Neufeld EF
    Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14870-5. PubMed ID: 25267636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal MRI brain volume changes over one year in children with mucopolysaccharidosis types IIIA and IIIB.
    Abreu NJ; Selvaraj B; Truxal KV; Moore-Clingenpeel M; Zumberge NA; McNally KA; McBride KL; Ho ML; Flanigan KM
    Mol Genet Metab; 2021 Jun; 133(2):193-200. PubMed ID: 33962822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease modeling for Mucopolysaccharidosis type IIIB using patient derived induced pluripotent stem cells.
    Huang W; Cheng YS; Yang S; Swaroop M; Xu M; Huang W; Zheng W
    Exp Cell Res; 2021 Oct; 407(1):112785. PubMed ID: 34411609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective one-year natural history study of mucopolysaccharidosis types IIIA and IIIB: Implications for clinical trial design.
    Truxal KV; Fu H; McCarty DM; McNally KA; Kunkler KL; Zumberge NA; Martin L; Aylward SC; Alfano LN; Berry KM; Lowes LP; Corridore M; McKee C; McBride KL; Flanigan KM
    Mol Genet Metab; 2016 Nov; 119(3):239-248. PubMed ID: 27590925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restoration of central nervous system alpha-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type 2 vector delivery.
    Fu H; DiRosario J; Kang L; Muenzer J; McCarty DM
    J Gene Med; 2010 Jul; 12(7):624-33. PubMed ID: 20603889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BMN 250, a fusion of lysosomal alpha-N-acetylglucosaminidase with IGF2, exhibits different patterns of cellular uptake into critical cell types of Sanfilippo syndrome B disease pathogenesis.
    Yogalingam G; Luu AR; Prill H; Lo MJ; Yip B; Holtzinger J; Christianson T; Aoyagi-Scharber M; Lawrence R; Crawford BE; LeBowitz JH
    PLoS One; 2019; 14(1):e0207836. PubMed ID: 30657762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB.
    Ohmi K; Greenberg DS; Rajavel KS; Ryazantsev S; Li HH; Neufeld EF
    Proc Natl Acad Sci U S A; 2003 Feb; 100(4):1902-7. PubMed ID: 12576554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.